Navigation Links
New Chemo Drug May Benefit Some Breast Cancer Patients
Date:3/2/2011

WEDNESDAY, March 2 (HealthDay News) -- The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment, according to a new study.

The researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.

The study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.

The most common side effects in both groups were fatigue and depletion of white blood cells. Numbness and pain stemming from nerve damage were the most common adverse event connected to eribulin that led women to drop out of the study (24, or 5 percent).

The study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin. Dr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.

"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit," the authors wrote.

In a related editorial, Drs. Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: "EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer. And that evidence suggests that the methods to treat advanced breast cancer are growing, the treatment challenge in refractory disease is a little bit less daunting, and the treatment results are a little bit better than they were before."

Commenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, "The findings of this trial are exciting because they will propel eribulin into wider use. This drug shows much promise, and it should certainly be included in additional trials to fully establish its benefit."

"It would be interesting to see if the drug offers the same benefit in women that have not been treated with multiple drugs before exposure to eribulin," she added.

More information

The Metastatic Breast Cancer Network has more about metastatic breast cancer.

-- Robert Preidt

SOURCE: Stephanie Bernik, M.D., F.A.C.S., chief of surgical oncology at Lenox Hill Hospital, New York City, N.Y.; The Lancet, news release, March 2, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. BUSM study shows chemoradiotherapy prior to surgery improves survival
2. Fish oil fights weight loss due to chemotherapy
3. Pot Ingredient May Restore Appetite After Chemo
4. Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
5. Stray Breast Tumor Cells in Early Chemo Could Be Bad Sign
6. Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
7. Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival
8. Surgery complications linked to chemotherapy delay, U-M study finds
9. Breast cancer: Reducing the risk of unnecessary chemo
10. Combining radiation therapy, chemotherapy safely treats head and neck cancer patients
11. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Chemo Drug May Benefit Some Breast Cancer Patients
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Sterling Global ... feature a unique and patented refillable hanging wipe dispenser. The campaign kick-off video is ... and will end June 25, 2016. The goal is to raise $1,000 per day ...
(Date:5/24/2016)... ... , ... To better understand the impact of lung cancer in women, the ... lung cancer. Today, the Lung Association announced Sharad Goyal, MD , as the recipient ... the American Lung Association’s LUNG FORCE initiative, which raises awareness of the impact of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... corporate identity and website at its “Transforming Outcomes” User Conference in Las Vegas ... reflect i2i’s ongoing success to set the market standard for meaningful population health ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... of communication enabled solutions and managed services today announced a strategic partnership ... enterprise contact center market. , Altura, one of Avaya’s largest Platinum Business ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... How to ... · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the ... that human error will ever be totally eliminated, many human performance problems can be ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
(Date:5/24/2016)... 2016 Les ... la première endoprothèse à double thérapie au ... portant sur les membres inférieurs et la ... entreprise mondiale spécialisée dans la fourniture de ... a élargi son portefeuille pour inclure des ...
(Date:5/24/2016)... May 24, 2016 Dutch surgeons have launched ... around the world and treat patients on a global scale. Medical ... , Asia and the US have already ... messaging and networking in a totally secure environment. Education  ... war zone working together with a surgeon at Harvard to treat ...
Breaking Medicine Technology: